Comparisons of Gut Microbiota Among Healthy Control, Patients With Conventional Adenoma, Sessile Serrated Adenoma, and Colorectal Cancer

Hyuk Yoon¹, Nayoung Kim¹,², Ji Hyun Park², Yong Sung Kim³, Jongchan Lee¹, Hyoung Woo Kim¹, Yoon Jin Choi¹, Cheol Min Shin¹, Young Soo Park¹, Dong Ho Lee¹,², Hyun Chae Jung²

¹Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, ²Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, ³Gastroenterology and Digestive Disease Research Institute, Wonkwang University Sanbon Hospital, Gunpo, Korea

Background: Studies on gut microbiota regarding colorectal carcinogenesis, including sessile serrated adenoma (SSA), have been scarce. The aim of this study is to investigate the role of mucosa-associated gut microbiota in the colorectal carcinogenesis.

Methods: We collected biopsy samples of normal rectal mucosa during colonoscopy from healthy control and patients with conventional adenoma, SSA, and colorectal cancer (CRC), respectively (n = 6). Pyrosequencing for 16S rRNA gene of bacteria was performed to compare gut microbiota.

Results: The most abundant phylum in total samples was Proteobacteria (55.6%), followed by Firmicutes (27.4%) and Bacteroidetes (11.6%). There was no significant difference in relative abundance of the phylum level among the four groups. Fusobacterium nucleatum, known to be frequently detected during colorectal carcinogenesis, was found in only one sample of patient with SSA. The rarefaction curves showed that the diversity of mucosal communities of patients with CRC is the lowest among the four groups and the diversity of mucosal communities of patients with SSA is higher than that of healthy control. Among the four groups, Shannon’s and Simpson’s index for diversity was the lowest and the highest in the patients with CRC, respectively; it did not reach statistical significance. The proportion of genus Pseudomonas was very high in the samples of patients with stage II-IV CRC compared with those with stage I CRC (59.3% vs. 0.3%, P = 0.064).

Conclusions: Our study suggests no significant role of mucosa-associated gut microbiota in the colorectal carcinogenesis. Further study for many samples or using fecal material could be helpful.

(J Cancer Prev 2017;22:108-114)

Key Words: Microbiota, Colonic neoplasms, Colon cancer, Colon adenoma, Sessile serrated adenoma

INTRODUCTION

Chronic inflammation following chronic infection is one of the main mechanism in human carcinogenesis. Development of gastric cancer after long-time Helicobacter pylori infection is a typical example.¹ The role of single pathogen in colorectal carcinogenesis was also studied for a long time. Fusobacterium nucleatum, Escherichia coli, Enterococcus faecalis, Streptococcus gallolyticus, and enterotoxigenic Bacteroides fragilis are candidate microorganisms that were pointed out as initial triggers in the development of colorectal cancer (CRC). It was reported that these bacteria are related with CRC in epidemiology and the possibility as causative microorganism in colorectal carcinogenesis was suggested by several animal models.² However, none of these bacteria succeeded to prove definite casual relation with CRC. At present, no study showed that
elimination of these organisms in human prevents CRC.

Recently, rapid development of new generation sequencing methods in the field of microorganism made it possible to identify gut microbiota that was unlikely to be culturable. In addition, these new technologies paved the path for analysis of massive genetic data of gut microbiota: metagenomics. Given this background, instead of single pathogen, the change in overall gut microbiota, interaction between each microbiota, and metabolites that bacteria produce are actively being studied in the field of colorectal carcinogenesis. It is well known that CRC usually develops through serial mutations after adenomatous change rather than de novo genesis. Therefore, researches regarding change of gut microbiota in adenomatous polyps that are precancerous lesions are also actively being carried out. Compared to healthy control, in the patients with adenomatous polyp and CRC, gut dysbiosis such as decreased diversity of gut microbiota is frequently observed. Increase of Fusobacterium and decrease of butyrate-producing bacteria are also suggested. Considering field cancerization, that is an important concept in the carcinogenesis, we can infer that these changes in gut microbiota would already occur not only in the neoplastic lesions but also in surrounding normal-looking mucosa. Actually, it was reported that gut microbiota of colorectal adenoma and near-by normal mucosa are similar to each other; but they are different from that of healthy control. In addition, Fusobacterium increased already in the normal rectal mucosa of patients with adenomatous polyps compared to that of healthy control.

Recently, sessile serrated adenoma (SSA) has received attention as a main cause of right colon cancer and interval CRC. SSA is known to progress to CRC through different pathway from conventional adenomatous polyp. Therefore, we can expect that the role and change of gut microbiota would be different from that in conventional adenomatous polyp. However, studies on gut microbiota regarding colorectal carcinogenesis including SSA have been scarce.

Gut microbiota can be largely divided into two groups depending on their anatomical localization: fecal-luminal microbiota and mucosa-associated microbiota. Fecal-luminal microbiota occupies the lumen of the intestine. It can be acquired relatively easily by collecting stool. Therefore, most large-scale studies regarding human gut microbiota including key studies, such as MetaHIT cohort and Human Microbiome Project analyzed fecal-luminal microbiota. However, fecal-luminal microbiota is more transient and it is more affected by diet than mucosa-associated microbiota. Mucosa-associated microbiota resides on the surface of the intestinal epithelium. Because it is more consistent and interacts with host cells more directly and intimately than fecal-luminal microbiota, it is considered more closely related with CRC. Nevertheless, to acquire it, endoscopic biopsy which is invasive procedure is required and bowel preparation for colonoscopy can change mucosa-associated microbiota. Therefore, studies for gut microbiota and CRC often used fecal-luminal microbiota rather than mucosa-associated microbiota.

From this background, the aim of this study is to compare mucosa-associated gut microbiota among healthy control, patients with conventional adenoma, SSA, and CRC.

**MATERIALS AND METHODS**

1. Subjects and tissue preparation

We collected biopsy samples of normal rectal mucosa during colonoscopy from four different groups: healthy control, patients with conventional adenoma, SSA and CRC, respectively. Rectal mucosal tissues of healthy control were acquired from subjects with normal proximal rectum (at approximately 18 cm from anal verge) by colonoscopic biopsy. The material was centrifuged at 20,000 ×g for 30 minutes to pellet bacteria. The pellet was processed to extract total microbial DNA using a commercial kit (iNtRON Biotechnology, Seongnam, Korea). This study was approved by the Institutional Review Board of the Seoul National University Hospital (IRB No. B-1308/215-008). For the present study, subjects who had no synchronous adenomatous polyps among subjects with SSA were selected. Tissues of subjects with conventional adenoma and subjects with CRC were selected from tissue pools of professor NK. All subjects with adenomatous polyp who enrolled in the present study had advanced colorectal neoplasms defined as adenomatous polyp larger than 1 cm, with villous portion, or with high grade dysplasia. Sex and age within 3 years were matched for each group. We confirmed that there was no history of antibiotics administration within three months before the day of mucosal biopsy in all subjects. All mucosal samples were obtained from normal proximal rectum (at approximately 18 cm from anal verge) by colonoscopic biopsy. The material was centrifuged at 20,000 ×g for 30 minutes to pellet bacteria. The pellet was processed to extract total microbial DNA using a commercial kit (iNtRON Biotechnology, Seongnam, Korea). This study was approved by the Institutional Review Board of the Seoul National University Hospital (IRB No. B-1308/215-008).

2. Barcoded 454-pyrosequencing of the 16S rRNA gene

DNA samples from four groups were subjected to pyrosequencing. PCR amplification was performed using primers
targeting the V1 to V3 regions of the 16S rRNA gene from extracted DNA. For bacterial amplification, barcoded primers of 9F (5′-CCATCCCTGTGCTGCAGCGTCAC-TCAG-AC-AGATTTGTA TCGTGGCTCAG-3′; underlined sequence indicates the target region primer) and 541R (5′-CATCTCATCCCTGCTGTCAC-TCAG-X-AC-ATTACCGCGGCTGCTGG-3′; ‘X’ indicates the unique barcode for each subject) (http://oklbb.ezbiocloud.net/content/1001) were used. Amplifications were carried out using an initial denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, primer annealing at 55°C for 45 seconds, and extension at 72°C for 90 seconds, with a final elongation at 72°C for 5 minutes. PCR products were analyzed by 2% agarose gel electrophoresis and visualized using a Gel Doc system (BioRad, Hercules, CA, USA). The amplified products were purified with the QiAquick PCR purification kit (Qiagen, Valencia, CA, USA). Equal concentrations of purified products were pooled together, and short concentrations (non-target products) were removed with Ampure beads kit (Agencourt Bioscience, Beverly, MA, USA). The quality and product size were assessed on a Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) using a DNA 7500 chip. Mixed amplicons were subjected to emulsion PCR, and then deposited on Picotiter plates. The sequencing was carried out at Chunlab Inc. (Seoul, Korea) with GS Junior Sequencing system, the modified laboratory benchtop form of 454 sequencing systems (Roche, Branford, CT, USA) according to the manufacturer’s instructions.

3. Pyrosequencing data analysis

Reads obtained from different samples were sorted by unique barcodes of each PCR product. The barcode, linker, and primer sequences were removed from the original sequencing reads. Reads containing two or more ambiguous nucleotides, reads with a low quality score (average score < 25), or reads shorter than 300 bp, were discarded. Potential chimeric sequences were detected by the Bellerophon method, which compares the BLASTN search results between the forward half and reverse half sequences.13 After removing the chimeric sequences, the taxonomic classification of each read was assigned against the EzTaxon-e database (http://eztaxon-e.ezbiocloud.net),14 which contains the 16S rRNA gene sequence of type strains that have valid published names and representative species level phylotypes of either cultured or uncultured entries in the GenBank database with complete hierarchical taxonomic classification from the phylum to the species.

The richness and diversity of samples were determined by abundance-based coverage estimators (ACE), Chao1 and Jackknife estimation. In addition, Simpson diversity index and Shannon diversity index at 3% distance were calculated in the CL community program (Chunlab Inc.). Good’s method was used to calculate sequencing coverage.15 Random subsampling was conducted to equalize the read size of samples for comparing different read sizes among samples. To compare the operational taxonomic units (OTUs) between samples, shared OTUs were obtained with the XOR analysis of the CL community program (Chunlab Inc.). UniFrac-based principal coordinates analysis was used to compare the microbial communities of sub-groups.

4. Statistical analysis

PASW for Windows ver. 18.0 (IBM Co., Armonk, NY, USA) was used for the statistical analysis. Because the data was not normally distributed (as demonstrated by the Shapiro-Wilk test), quantititative variables among four groups were compared using a Kruskal-Wallis test. Post hoc comparisons of pairwise differences between two groups were evaluated by the Mann-Whitney U-test using the modified Bonferroni procedure for multiple com-

| Characteristic                  | Control (n = 6) | ACN (n = 6) | SSA (n = 6) | CRC (n = 6) | P-value |
|--------------------------------|----------------|-------------|-------------|-------------|---------|
| Valid reads (median)           | 1,435          | 3,374       | 2,557       | 3,929       | 0.551   |
| OTUs (median)                  | 131            | 128         | 80          | 101         | 0.684   |
| Good’s library coverage (%)    | 96.0           | 97.3        | 95.9        | 98.8        | 0.470   |
| Diversity index (median)       | 0.10           | 0.06        | 0.14        | 0.16        | 0.584   |

ACN: advanced colorectal neoplasm; SSA: sessile serrated adenoma; CRC: colorectal cancer; OTU: operational taxonomic units; ACE: abundance-based coverage estimators.
parison adjustment. All results were considered statistically significant when *P*-values were less than 0.05.

**RESULTS**

1. Relative abundance of mucosal associated microbiota

Total 24 subjects were enrolled in the present study: three subjects by each sex in four groups. There was no significant difference in the mean age among the four groups. (mean, 61.75 ± 10.86, *P* = 0.791). The basal characteristics of pyrosequencing data analysis and species richness indicators in the rectal mucosa samples are shown in Table 1. The mean number of total and valid 16s rRNA reads for each sample was 6,070 and 3,022, respectively. The most abundant phylum in total samples was Proteobacteria (55.6%), followed by Firmicutes (27.4%), Bacteroidetes (11.6%), Fusobacteria (3.2%), and Actinobacteria (1.7%). Figure 1 shows relative abundance of the phylum level in the rectal mucosa samples by pyrosequencing. There was no significant difference in relative abundance of most abundant phyla among the four groups (*P* > 0.05). Relative abundance of microbiota among the four groups was not significantly different in the genus level (Fig. 2). The most abundant species in total samples was *E. coli* (24.6%), followed by *Pseudomonas cremoris* (21.7%) and *Rhizobium leguminosarum* (8.0%). *F. nucleatum*, which is known to be frequently detected in patients with CRC, was found in only one sample of patient with SSA. The percentage of *F. nucleatum* sequence was also very low in that sample (0.04%). The abundance of *Faecalibacterium prausnitzii* and *Roseburia hominis* that are principle ones of butyrate-producing bacteria were not different among the four groups.

2. Alpha-diversity

The overall Good’s coverage was 96.1%. Figure 3 shows rarefaction curve for the comparison of the microbial communities in the rectal mucosa samples. The rarefaction curves shows that the diversity of mucosal communities of subjects with CRC is the lowest among the four groups and the diversity of mucosal communities of subjects with SSA is higher than that of healthy control. Species richness indicators such as ACE, Chao1, and Jackknife were not different among the four groups (Table 1). Shannon’s index for diversity was the lowest and Simpson’s index for diversity was the highest in the subjects with CRC among the four groups, although they did not reach statistical significance.

3. Beta-diversity

Figure 4 shows un-weighted UniFrac-based principal coordinates analysis of the microbial communities in the rectal mucosa. The samples were not definitely separated according to their groups. However, four samples from CRC patients with stage II-IV
Table 2. Clinicopathologic data of six patients with colorectal cancer

| Sample name | Sex | Age (yr) | Location of cancer | TNM classification | Stage |
|-------------|-----|----------|--------------------|--------------------|-------|
| CC 7        | F   | 50       | Rectum             | T3N1bM0            | IIIB  |
| CC 8        | M   | 58       | Rectum             | T3N0M0             | IIA   |
| CC 9        | F   | 55       | S-colon            | T2N0M0             | I     |
| CC 10       | M   | 55       | Rectum             | T3N2M1             | IV    |
| CC 11       | F   | 78       | S-colon            | T2N0M0             | I     |
| CC 12       | M   | 79       | Cecum              | T3N2bM0            | IIIC  |

F, female; M, male; S, sigmoid. *Stage was defined by the American Joint Committee on Cancer Cancer Staging Manual, 7th edition (2010).

**DISCUSSION**

When there is change in the gut microbiota in patient with colorectal neoplasm, it is very difficult to determine whether it is cause or consequence of colorectal neoplasm. Tjalsma et al. reported bacterial driver-passenger model for CRC. They suggested that change of gut microbiota in the neoplastic tissue is useful to determine passenger bacteria and change of gut microbiota in non-neoplastic tissue is rather helpful to decide driver bacteria. Based on this study, we analyzed gut microbiota of normal-looking mucosa of the subjects. Overall results showed that there was no significant difference in mucosa-associated gut microbiota among healthy control, patients with conventional adenoma, SSA, and CRC. However, this finding is likely related to low power stemming from small sample size. In the rarefaction curve, we found tendency of decreasing diversity of gut microbiota from healthy control to advanced colorectal neoplasm and CRC group. This finding corresponds well with the results of earlier studies which reported that diversity of mucosa-associated gut microbiota among healthy control, patients with conventional adenoma or CRC decreased compared to that of healthy control. On the contrary, gut microbiota of SSA group showed higher diversity than that of healthy control in the rarefaction curve. This result implies that the change of gut microbiota in patients with SSA differs from change during conventional adenoma-carcinoma sequence. Similarly to our results, Peters et al. reported that SSA did not differ in diversity or composition from controls and few taxa were differentially abundant between SSA cases and controls. They suggested that gut microbiota may play a role in colorectal carcinogenesis through the development of conventional adenoma only. Our finding compensates Peters et al.'s study which has limitation in that it is derived from analysis of fecal-luminal microbiota.
In a large study regarding premalignant lesions and CRC including SSA, Ito et al. reported that *F. nucleatum* was identified in premalignant colorectal lesions regardless of histopathology. Because this study used qPCR for identification of *F. nucleatum* instead of metagenomics, it is inappropriate to compare it directly with our study. Nevertheless, *F. nucleatum* was observed in a very low frequency in the samples of our study and we speculated this due to small sample size.

Definite separation of gut microbiota according to each group was not found in PCoA analysis in the present study. However, interestingly, gut microbiota of patients with stage II or higher CRC was separated from that of patients with stage I CRC. Specifically, the proportion of genus *Pseudomonas* was very high in the samples of patients with stage II or higher CRC. Because we collected mucosal samples of CRC patients before the start of treatment, such as surgery or chemotherapy, we speculated that *Pseudomonas* might be passenger bacteria which rapidly increase after change of intestinal milieu as CRC progresses. However, we could not find any article supporting our finding. Instead, it was reported that Enterobacteriaceae which is a branch of Proteobacteria same as *Pseudomonas* and contains genera such as *E. coli*, *Klebsiella spp.*, and *Proteus spp.* blooms in the inflamed microenvironment in the gut. Further studies using many samples are required for the investigating the role of *Pseudomonas* during colorectal carcinogenesis.

This study has several limitations. It is well known that the proportion of Proteobacteria is higher in mucosa-associated microbiota than in fecal-luminal microbiota. Nevertheless, the proportion of Proteobacteria in all groups is excessively high compared to other studies. Considering that Proteobacteria is ubiquitous bacteria in the ecosystem, we cannot exclude the possibility that the samples were contaminated at some stage. Therefore, we reviewed whole process from tissue sampling to bacterial DNA sequencing; but we could not find any problematic steps in particular. In addition, because the sample size was too small for each group, it is very difficult to make a definite conclusion regarding gut microbiota during colorectal carcinogenesis based on the results of this study alone.

Our study suggests no significant role of mucosa-associated gut microbiota in the colorectal carcinogenesis. Further study for many samples or using fecal material could be helpful.

**ACKNOWLEDGMENTS**

This work was supported by the National Research Foundation of Korea (NRF) grant for the Global Core Research Center (GCRC) funded by the Korea government (MSIP) (No. 2011-0030001).

**CONFLICTS OF INTEREST**

No potential conflicts of interest were disclosed.

**REFERENCES**
senger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012;10:575-82.
18. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012;7:e90743.
19. Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013;105:1907-11.
20. Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome 2016;4:69.
21. Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015;137:1258-68.
22. Zeng MY, Inohara N, Núñez G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol 2017;10:18-26.
23. Ringel Y, Maharshak N, Ringel-Kulka T, Wolber EA, Sartor RB, Carroll IM. High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individuals. Gut Microbes 2015;6:173-81.
24. Durbán A, Abellán JJ, Jiménez-Hernández N, Ponce M, Ponce J, Sala T, et al. Assessing gut microbial diversity from feces and rectal mucosa. Microb Ecol 2011;61:123-33.
25. Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 2015;33:496-503.